Cargando…

Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial

Oncolytic virotherapy may be a means of improving the dismal prognosis of malignant brain tumors. The rat H-1 parvovirus (H-1PV) suppresses tumors in preclinical glioma models, through both direct oncolysis and stimulation of anticancer immune responses. This was the basis of ParvOryx01, the first p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Geletneky, Karsten, Hajda, Jacek, Angelova, Assia L., Leuchs, Barbara, Capper, David, Bartsch, Andreas J., Neumann, Jan-Oliver, Schöning, Tilman, Hüsing, Johannes, Beelte, Birgit, Kiprianova, Irina, Roscher, Mandy, Bhat, Rauf, von Deimling, Andreas, Brück, Wolfgang, Just, Alexandra, Frehtman, Veronika, Löbhard, Stephanie, Terletskaia-Ladwig, Elena, Fry, Jeremy, Jochims, Karin, Daniel, Volker, Krebs, Ottheinz, Dahm, Michael, Huber, Bernard, Unterberg, Andreas, Rommelaere, Jean
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768665/ https://www.ncbi.nlm.nih.gov/pubmed/28967558 http://dx.doi.org/10.1016/j.ymthe.2017.08.016

Ejemplares similares

Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity
por: Angelova, Assia L., et al.
Publicado: (2017)

Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol
por: Geletneky, Karsten, et al.
Publicado: (2012)

A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol
por: Hajda, Jacek, et al.
Publicado: (2017)

Tumor Selectivity of Oncolytic Parvoviruses: From in vitro and Animal Models to Cancer Patients
por: Angelova, Assia L., et al.
Publicado: (2015)

Stability and safety key factors of the oncolytic protoparvovirus H-1 from manufacturing to human application
por: Frehtman, Veronika, et al.
Publicado: (2023)

A novel scalable, robust downstream process for oncolytic rat parvovirus: isoelectric point-based elimination of empty particles
por: Leuchs, Barbara, et al.
Publicado: (2017)

Improved Killing of Human High-Grade Glioma Cells by Combining Ionizing Radiation with Oncolytic Parvovirus H-1 Infection
por: Geletneky, Karsten, et al.
Publicado: (2010)

Immune System Stimulation by Oncolytic Rodent Protoparvoviruses
por: Angelova, Assia, et al.
Publicado: (2019)

Parvovirus-Based Combinatorial Immunotherapy: A Reinforced Therapeutic Strategy against Poor-Prognosis Solid Cancers
por: Angelova, Assia, et al.
Publicado: (2021)

Oncolytic parvoviruses: from basic virology to clinical applications
por: Marchini, Antonio, et al.
Publicado: (2015)

The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers
por: Angelova, Assia L., et al.
Publicado: (2017)

Extent of Resection, MGMT Promoter Methylation Status and Tumor Location Independently Predict Progression-Free Survival in Adult Sporadic Pilocytic Astrocytoma
por: Jungk, Christine, et al.
Publicado: (2019)

Prognostic value of the extent of resection in supratentorial WHO grade II astrocytomas stratified for IDH1 mutation status: a single-center volumetric analysis
por: Jungk, Christine, et al.
Publicado: (2016)

Evaluation of the Becton Dickinson Rapid Influenza Diagnostic Tests in Outpatients in Germany during Seven Influenza Seasons
por: Eggers, Maren, et al.
Publicado: (2015)

Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients
por: Jungk, Christine, et al.
Publicado: (2016)

Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study
por: Marchini, Antonio, et al.
Publicado: (2019)

Mutation specific antibodies: tool or dinosaur?
por: von Deimling, Andreas, et al.
Publicado: (2012)

Defining the timing of respiratory syncytial virus (RSV) outbreaks: an epidemiological study
por: Terletskaia-Ladwig, Elena, et al.
Publicado: (2005)

Location-Dependent Patient Outcome and Recurrence Patterns in IDH1-Wildtype Glioblastoma
por: Jungk, Christine, et al.
Publicado: (2019)

Generation and Validation of Monoclonal Antibodies Suitable for Detecting and Monitoring Parvovirus Infections
por: Tessmer, Claudia, et al.
Publicado: (2022)

Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone
por: Jungk, Christine, et al.
Publicado: (2016)

Clinical neuropathology practice news 2-2012: BRAF V600E testing
por: Capper, David, et al.
Publicado: (2012)

Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1
por: Moehler, Markus, et al.
Publicado: (2011)

Preclinical Testing of an Oncolytic Parvovirus: Standard Protoparvovirus H-1PV Efficiently Induces Osteosarcoma Cell Lysis In Vitro
por: Geiss, Carsten, et al.
Publicado: (2017)

Upstream process optimization and micro- and macrocarrier screening for large-scale production of the oncolytic H-1 protoparvovirus
por: Wohlfarth, Daniel, et al.
Publicado: (2021)

Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT
por: Jungwirth, Gerhard, et al.
Publicado: (2019)

Immunity status of adults and children against poliomyelitis virus type 1 strains CHAT and Sabin (LSc-2ab) in Germany
por: Eggers, Maren, et al.
Publicado: (2010)

TLR-9 Contributes to the Antiviral Innate Immune Sensing of Rodent Parvoviruses MVMp and H-1PV by Normal Human Immune Cells
por: Raykov, Zahari, et al.
Publicado: (2013)

Frame-based stereotactic biopsies using an intraoperative MR-scanner are as safe and effective as conventional stereotactic procedures
por: Neumann, Jan-Oliver, et al.
Publicado: (2018)

Interdisciplinary approach allows minimally invasive, nerve-sparing removal of retroperitoneal peripheral nerve sheath tumors
por: Hajiabadi, Mohammed Mehdi, et al.
Publicado: (2020)

Oncolytic Rodent Protoparvoviruses Evade a TLR- and RLR-Independent Antiviral Response in Transformed Cells
por: Angelova, Assia, et al.
Publicado: (2023)

PATH-04. AN ENHANCED AI-DRIVEN PLATFORM FOR PRECISION MOLECULAR BRAIN TUMOR DIANOSTICS
por: Sill, Martin, et al.
Publicado: (2020)

Pediatric and Adult High-Grade Glioma Stem Cell Culture Models Are Permissive to Lytic Infection with Parvovirus H-1
por: Josupeit, Rafael, et al.
Publicado: (2016)

Increased Radiation-Associated T-Cell Infiltration in Recurrent IDH-Mutant Glioma
por: Makarevic, Anastasia, et al.
Publicado: (2020)

Risk Estimation in Non-Enhancing Glioma: Introducing a Clinical Score
por: Dao Trong, Philip, et al.
Publicado: (2023)

Oncolytic effects of parvovirus H-1 in medulloblastoma are associated with repression of master regulators of early neurogenesis
por: Lacroix, Jeannine, et al.
Publicado: (2014)

Preclinical Testing of an Oncolytic Parvovirus in Ewing Sarcoma: Protoparvovirus H-1 Induces Apoptosis and Lytic Infection In Vitro but Fails to Improve Survival In Vivo
por: Lacroix, Jeannine, et al.
Publicado: (2018)

LGG-33. ISOMORPHIC DIFFUSE GLIOMA HAS RECURRENT GENE FUSIONS OF MYBL1 OR MYB AND CAN BE DISTINGUISHED FROM OTHER MYB/MYBL1 ALTERED GLIOMAS BASED ON A DISTINCT MORPHOLOGY AND DNA METHYLATION PROFILE
por: Wefers, Annika K, et al.
Publicado: (2020)

Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients
por: Mock, Andreas, et al.
Publicado: (2015)

The anesthetist’s choice of inhalational vs. intravenous anesthetics has no impact on survival of glioblastoma patients
por: Schmoch, Thomas, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7l2sbv111fo63ovkc08lc16pgv